Stallergenes to Drop Former Nestlé Peanut Allergy Pill Palforzia

The owner of the peanut allergy treatment Palforzia will abandon it less than three years after buying it from Nestlé, underscoring the disappointment of a product once billed as a potential blockbuster.

Commercialization will end on July 31, with production winding down in phases, closely held Stallergenes Greer said on the Palforzia website. The plan is voluntary and unrelated to safety or efficacy, the company said. It did not immediately return an email and a call seeking comment.